Skip to the main content

Reumatizam, Vol. 52 No. 1, 2005.

Review article

Quo vadetis coxibes?

Simeon Grazio ; Clinic for Rheumatology, Physical Medicine and Rehabilitation, Clinical Hospital “Sestre milosrdnice”, Zagreb, Croatia
Branimir Anić ; Department for Clinical Immunology and Rheumatology, Clinic for Internal Medicine, Clinical Hospital Centre Zagreb, Zagreb, Croatia

Full text: croatian pdf 472 Kb

page 17-27

downloads: 442

cite

Abstract

After the withdrawall of rofecoxib from worldwide market, there is ongoing debate whether gastrointestinal safety of COX-2 inhibition compared to non-selective NSAID-s may come at the cost of increased cardiovascular events. In this paper the relevant data regarding mechanisms, effects and side effects of selected COX-2 inhibitors are presented. Possible class effect is disscused and proposed alternative therapies.

Keywords

selective cyclooxigenase-2 inhibitors; non-steroidal antiinflammatory drugs; cardiovascular effect

Hrčak ID:

125959

URI

https://hrcak.srce.hr/125959

Publication date:

1.7.2005.

Article data in other languages: croatian

Visits: 1.599 *